Asenapine (BioDeep_00000719863)

   


代谢物信息卡片


(3aS,12bS)-2-Methyl-2,3,3a,12b-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrole

化学式: C17H16ClNO (285.0920356)
中文名称: 阿塞那平API杂质, 阿塞那平
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: ClC1=CC=C2OC3=CC=CC=C3[C@@](C4)([H])[C@](CN4C)([H])C2=C1
InChI: InChI=1S/C17H16ClNO/c1-19-9-14-12-4-2-3-5-16(12)20-17-7-6-11(18)8-13(17)15(14)10-19/h2-8,14-15H,9-10H2,1H3

描述信息

N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AH - Diazepines, oxazepines, thiazepines and oxepines
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents
D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants
An organic heterotetracyclic compound that is 2,3,3a,12b-tetrahydrodibenzo[2,3:6,7]oxepino[4,5-c]pyrrole bearing methyl and chloro substituents at positions 2 and 5 respectively.
C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent
Asenapine (Org 5222), an atypical antipsychotic, is an antagonist of serotonin receptors (pKi: 8.4-10.5), adrenoceptors (pKi: 8.9-9.5), dopamine receptors (pKi: 8.9-9.4) and histamine receptors (pKi: 8.2-9.0). Asenapine can be used in the research of schizophrenia and bipolar disorder[1][2].

同义名列表

5 个代谢物同义名

(3aS,12bS)-2-Methyl-2,3,3a,12b-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrole; (R,R)-asenapine; Asenapine; 5-Chloro-2-methyl-2,3,3a,12b-tetrahydrodibenzo[2,3:6,7]oxepino[4,5-c]pyrrole; Org 5222



数据库引用编号

19 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Shoujun Ren, Chao Liu, Yutong Sun, Yang Zhang, Jiuheng Ruan, Liang Fang. Formulation Development and Molecular Mechanism Characterization of Long-Acting Patches of Asenapine for Efficient Delivery by Combining API-ILs Strategy and Controlled-Release Polymers. Journal of pharmaceutical sciences. 2023 07; 112(7):1850-1862. doi: 10.1016/j.xphs.2023.02.002. [PMID: 36858176]
  • Renuka Suresh Managuli, Meka Sreenivasa Reddy, Kunnatur Balasundara Koteshwara, Srinivas Mutalik. Enteric coating of nanostructured lipid carriers (NLCs) and enteric coating of hard gelatin capsules filled with NLCs: Feasibility studies. Pakistan journal of pharmaceutical sciences. 2021 Jul; 34(4):1323-1331. doi: ". [PMID: 34799304]
  • Hui-Hui Wu, Ting-Ting Meng, Jia-Min Chen, Fan-Liang Meng, Shu-Ya Wang, Rong-Han Liu, Jia-Nan Chen, Bin Ning, Ying Li, Guo-Hai Su. Asenapine maleate inhibits angiotensin II-induced proliferation and activation of cardiac fibroblasts via the ROS/TGFβ1/MAPK signaling pathway. Biochemical and biophysical research communications. 2021 05; 553(?):172-179. doi: 10.1016/j.bbrc.2021.03.042. [PMID: 33773140]
  • Zackary A Cope, Johnny A Kenton, Arpi Minassian, Maureen V Martin, William Perry, Christoffer Bundgaard, Jørn Arnt, Jordy van Enkhuizen, Mark A Geyer, Jared W Young. Chronic antipsychotic treatment exerts limited effects on the mania-like behavior of dopamine transporter knockdown mice. Behavioural brain research. 2021 05; 405(?):113167. doi: 10.1016/j.bbr.2021.113167. [PMID: 33577882]
  • Katsumi Suzuki, Mariacristina Castelli, Marina Komaroff, Brittney Starling, Takaaki Terahara, Leslie Citrome. Pharmacokinetic Profile of the Asenapine Transdermal System (HP-3070). Journal of clinical psychopharmacology. 2021 May; 41(3):286-294. doi: 10.1097/jcp.0000000000001383. [PMID: 33734167]
  • Federica Fiaschè, Barbara Adriani, Iginia Mancinelli, Aldo Taranto. Treatment of Catatonia with Asenapine in a Patient with Schizotypal Personality Disorder, Psychotic Depression and Septic Shock from SARSCoV- 2 - A Case Report. CNS & neurological disorders drug targets. 2021; 20(5):473-477. doi: 10.2174/1871527320666210226114238. [PMID: 33634761]
  • Rif S El-Mallakh, Sharon Nuss, Dong Gao, Yonglin Gao, Surriya Colleen Ahmad, Clare Schrodt, Caleb Adler. Asenapine in the Treatment of Bipolar Depression. Psychopharmacology bulletin. 2020 03; 50(1):8-18. doi: ". [PMID: 32214517]
  • Mitali Patel, Veenu Mundada, Krutika Sawant. Enhanced intestinal absorption of asenapine maleate by fabricating solid lipid nanoparticles using TPGS: elucidation of transport mechanism, permeability across Caco-2 cell line and in vivo pharmacokinetic studies. Artificial cells, nanomedicine, and biotechnology. 2019 Dec; 47(1):144-153. doi: 10.1080/21691401.2018.1546186. [PMID: 30669881]
  • Nejal M Bhatt, Vijay D Chavada, Mallika Sanyal, Pranav S Shrivastav. Densitometry and indirect normal-phase HPTLC-ESI-MS for separation and quantitation of drugs and their glucuronide metabolites from plasma. Biomedical chromatography : BMC. 2019 Oct; 33(10):e4602. doi: 10.1002/bmc.4602. [PMID: 31116448]
  • Renuka S Managuli, Julie T Wang, Farid N Faruqu, Varun Kushwah, Sushil Y Raut, Ajjappla B Shreya, Khuloud T Al-Jamal, Sanyog Jain, Srinivas Mutalik. Asenapine maleate-loaded nanostructured lipid carriers: optimization and in vitro, ex vivo and in vivo evaluations. Nanomedicine (London, England). 2019 Apr; 14(7):889-910. doi: 10.2217/nnm-2018-0289. [PMID: 30874464]
  • Esen Gumuslu, Oguz Mutlu, Sibel Kokturk, Guner Ulak, Fatma Ceyla Eraldemir, Ozan Can Tatar, Alisan Burak Yasar, Pelin Tanyeri, Furuzan Akar, Faruk Erden. Effects of Asenapine and Paliperidone on Depression, Anxiety and Analgesy in Mice: Alterations in Brain Neurotrophic Factors, Neurogenesis, and Blood Enzyme Levels. The Chinese journal of physiology. 2018 Oct; 61(5):280-292. doi: 10.4077/cjp.2018.bah626. [PMID: 30384401]
  • Michele Protti, Alice Vignali, Teresa Sanchez Blanco, James Rudge, Francesca Bugamelli, Anna Ferranti, Roberto Mandrioli, Laura Mercolini. Enantioseparation and determination of asenapine in biological fluid micromatrices by HPLC with diode array detection. Journal of separation science. 2018 Mar; 41(6):1257-1265. doi: 10.1002/jssc.201701315. [PMID: 29266728]
  • Sanjay Kumar Singh, Mahendra Kumar Hidau, Shrikant Gautam, Kiran Gupta, Krishna Pal Singh, Shio Kumar Singh, Sanjay Singh. Glycol chitosan functionalized asenapine nanostructured lipid carriers for targeted brain delivery: Pharmacokinetic and teratogenic assessment. International journal of biological macromolecules. 2018 Mar; 108(?):1092-1100. doi: 10.1016/j.ijbiomac.2017.11.031. [PMID: 29126941]
  • Renuka S Managuli, Karthik Gourishetti, Rekha R Shenoy, Kunnatur B Koteshwara, Meka Sreenivasa Reddy, Srinivas Mutalik. Preclinical pharmacokinetics and biodistribution studies of asenapine maleate using novel and sensitive RP-HPLC method. Bioanalysis. 2017 Jul; 9(14):1037-1047. doi: 10.4155/bio-2017-0069. [PMID: 28737445]
  • Renuka S Managuli, Lalit Kumar, Ankita D Chonkar, Rupesh K Shirodkar, Shaila Lewis, Kunnatur B Koteshwara, Meka Sreenivasa Reddy, Srinivas Mutalik. Development and Validation of a Stability-Indicating RP-HPLC Method by a Statistical Optimization Process for the Quantification of Asenapine Maleate in Lipidic Nanoformulations. Journal of chromatographic science. 2016 Sep; 54(8):1290-300. doi: 10.1093/chromsci/bmw062. [PMID: 27130879]
  • Robert L Findling, Ronald L Landbloom, Armin Szegedi, Janelle Koppenhaver, Sabine Braat, Qi Zhu, Mary Mackle, Kiki Chang, Maju Mathews. Asenapine for the Acute Treatment of Pediatric Manic or Mixed Episode of Bipolar I Disorder. Journal of the American Academy of Child and Adolescent Psychiatry. 2015 Dec; 54(12):1032-41. doi: 10.1016/j.jaac.2015.09.007. [PMID: 26598478]
  • Hila M Ene, Nirit Z Kara, Haim Einat. The effects of the atypical antipsychotic asenapine in a strain-specific battery of tests for mania-like behaviors. Behavioural pharmacology. 2015 Jun; 26(4):331-7. doi: 10.1097/fbp.0000000000000128. [PMID: 25590966]
  • Chris A Oosterhof, Mostafa El Mansari, Pierre Blier. Asenapine alters the activity of monoaminergic systems following its subacute and long-term administration: an in vivo electrophysiological characterization. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2015 Apr; 25(4):531-43. doi: 10.1016/j.euroneuro.2015.01.006. [PMID: 25656272]
  • Peter Dogterom, Rik de Greef, Pierre A M Peeters. The effect of food on the high clearance drug asenapine after sublingual administration to healthy male volunteers. European journal of clinical pharmacology. 2015 Jan; 71(1):65-74. doi: 10.1007/s00228-013-1587-4. [PMID: 25552402]
  • Leslie Citrome. Asenapine review, part I: chemistry, receptor affinity profile, pharmacokinetics and metabolism. Expert opinion on drug metabolism & toxicology. 2014 Jun; 10(6):893-903. doi: 10.1517/17425255.2014.908185. [PMID: 24793403]
  • David E Kemp, Jun Zhao, Pilar Cazorla, Ronald P Landbloom, Mary Mackle, Linda Snow-Adami, Armin Szegedi. Weight change and metabolic effects of asenapine in patients with schizophrenia and bipolar disorder. The Journal of clinical psychiatry. 2014 Mar; 75(3):238-45. doi: 10.4088/jcp.12m08271. [PMID: 24499969]
  • Elena Grossini, Carla Gramaglia, Serena Farruggio, Kevin Bellofatto, Chiara Anchisi, David Mary, Giovanni Vacca, Patrizia Zeppegno. Asenapine increases nitric oxide release and protects porcine coronary artery endothelial cells against peroxidation. Vascular pharmacology. 2014 Mar; 60(3):127-41. doi: 10.1016/j.vph.2014.01.008. [PMID: 24512732]
  • Caitlin Miller, Oscar Pleitez, Dan Anderson, Diane Mertens-Maxham, Norman Wade. Asenapine (Saphris®): GC-MS method validation and the postmortem distribution of a new atypical antipsychotic medication. Journal of analytical toxicology. 2013 Oct; 37(8):559-64. doi: 10.1093/jat/bkt076. [PMID: 24009049]
  • W Pitchot. [Medication of the month. asenapine (Sycrest]. Revue medicale de Liege. 2013 Apr; 68(4):196-200. doi: NULL. [PMID: 23755711]
  • William V Bobo. Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. Expert review of clinical pharmacology. 2013 Jan; 6(1):61-91. doi: 10.1586/ecp.12.70. [PMID: 23272794]
  • Theo de Boer, Erik Meulman, Henri Meijering, Jaap Wieling, Peter Dogterom, Holger Lass. Development and validation of automated SPE-HPLC-MS/MS methods for the quantification of asenapine, a new antipsychotic agent, and its two major metabolites in human urine. Biomedical chromatography : BMC. 2012 Dec; 26(12):1461-3. doi: 10.1002/bmc.2722. [PMID: 22344545]
  • Marc De Hert, Weiping Yu, Johan Detraux, Kim Sweers, Ruud van Winkel, Christoph U Correll. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS drugs. 2012 Sep; 26(9):733-59. doi: 10.2165/11634500-000000000-00000. [PMID: 22900950]
  • Mireille G F Gerrits, Rik de Greef, Peter Dogterom, Pierre A M Peeters. Valproate reduces the glucuronidation of asenapine without affecting asenapine plasma concentrations. Journal of clinical pharmacology. 2012 May; 52(5):757-65. doi: 10.1177/0091270011404028. [PMID: 21628604]
  • Theo de Boer, Erik Meulman, Henri Meijering, Jaap Wieling, Peter Dogterom, Holger Lass. Quantification of asenapine and three metabolites in human plasma using liquid chromatography-tandem mass spectrometry with automated solid-phase extraction: application to a phase I clinical trial with asenapine in healthy male subjects. Biomedical chromatography : BMC. 2012 Feb; 26(2):156-65. doi: 10.1002/bmc.1640. [PMID: 21557265]
  • Pierre Peeters, Howard Bockbrader, Edwin Spaans, Peter Dogterom, Kenneth Lasseter, Thomas Marbury, Gordon L Gibson, Rik de Greef. Asenapine pharmacokinetics in hepatic and renal impairment. Clinical pharmacokinetics. 2011 Jul; 50(7):471-81. doi: 10.2165/11590490-000000000-00000. [PMID: 21651314]
  • S F M van de Wetering-Krebbers, P L Jacobs, G J Kemperman, E Spaans, P A M Peeters, L P C Delbressine, M L P S van Iersel. Metabolism and excretion of asenapine in healthy male subjects. Drug metabolism and disposition: the biological fate of chemicals. 2011 Apr; 39(4):580-90. doi: 10.1124/dmd.110.036715. [PMID: 21177986]
  • Claudine M Chwieduk, Lesley J Scott. Asenapine: a review of its use in the management of mania in adults with bipolar I disorder. CNS drugs. 2011 Mar; 25(3):251-67. doi: 10.2165/11206700-000000000-00000. [PMID: 21323396]
  • H Y Meltzer, B W Massey. The role of serotonin receptors in the action of atypical antipsychotic drugs. Current opinion in pharmacology. 2011 Feb; 11(1):59-67. doi: 10.1016/j.coph.2011.02.007. [PMID: 21420906]
  • S Chapel, M M Hutmacher, H Bockbrader, R de Greef, R L Lalonde. Comparison of QTc data analysis methods recommended by the ICH E14 guidance and exposure-response analysis: case study of a thorough QT study of asenapine. Clinical pharmacology and therapeutics. 2011 Jan; 89(1):75-80. doi: 10.1038/clpt.2010.220. [PMID: 21107314]
  • Steven G Potkin. Asenapine: a clinical overview. The Journal of clinical psychiatry. 2011; 72 Suppl 1(?):14-8. doi: 10.4088/jcp.10075su1.03. [PMID: 22217438]
  • Raymond A Lorenz, Cherry W Jackson, Marianne Saitz. Adjunctive use of atypical antipsychotics for treatment-resistant generalized anxiety disorder. Pharmacotherapy. 2010 Sep; 30(9):942-51. doi: 10.1592/phco.30.9.942. [PMID: 20795849]
  • Juliane Weber, Paul L McCormack. Asenapine. CNS drugs. 2009 Sep; 23(9):781-92. doi: 10.2165/11200860-000000000-00000. [PMID: 19689168]
  • Robert R Conley, Deanna L Kelly. Drug-drug interactions associated with second-generation antipsychotics: considerations for clinicians and patients. Psychopharmacology bulletin. 2007; 40(1):77-97. doi: NULL. [PMID: 17285099]
  • H M von dem Wildenberg, L P Delbressine, F M Kaspersen, G N Wagenaars, P L Jacobs. Biotransformation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1-H-dibenz[2,3:6,7]oxepin o [4,5-c]pyrrolidine maleate in rats. Arzneimittel-Forschung. 1990 May; 40(5):540-4. doi: NULL. [PMID: 1974431]